VISTIN PHARMA ASA
Sector unknown·VISTN · Oslo Børs·Fiscal year to 31/12/2024
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Diabetes care
Technology
DriverPositive impact: strengthens
“The growth of Metformin is driven by the growing number of people in the world who develops diabetes type 2. There is also growth in the number of people in low- and middle-income countries who get diagnosed and put on Metformin - being an efficient, cheap and safe drug treatment.”
Annual report 2024A · The company itself
DriverPositive impact: strengthens
“Diabetes is one of the largest global health crises of the 21st century, and the global demand for Metformin medication is expected to continue to grow by 4-6% CAGR, in the foreseeable future, as it remains the first line treatment for the main population of type 2 diabetes patients.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“Looking ahead into 2025 we are steadily ramping up the volume further and ensuring volumes to our customers growing demand, and we also actively work with introducing new customers to the benefits and quality of using our Metformin API.”
Annual report 2024A · The company itself
Market
“Vistin made a large investment in 2022 into a second parallel manufacturing line with the aim of reaching 7000 metric tons (MT). This was to support our existing customers growing demand for Metformin and to fuel further growth in the global market. Today Vistin has around 10% of the global market share of metformin API, and the market is showing an underlaying stable growth (CAGR) of 4-6% annually.”
Annual report 2024A · The company itself
Market
“Vistin Pharma is a major player and a wellrecognized global supplier of Metformin, the standard baseline treatment of diabetes II.”
Annual report 2024A · The company itself
Automation and robotics
Technology
StrategyPositive impact: strengthens
“Our focus in 2025 is to further increase the technical capacity and transform the additional volume into sales.”
Annual report 2024A · The company itself
Energy efficiency
Technology
StrategyPositive impact: strengthens
“Further to make our manufacturing site the most technology advanced and environmentally sustainable state of the art Metformin plant in the world.”
Annual report 2024A · The company itself
Chains in: Carbon tax and ETS prices strengthens, EU climate and energy policy strengthens
ESG and sustainability reporting
Regulation
StrategyPositive impact: strengthens
“Vistin has positioned itself as a premium supplier in the highly competitive metformin market, and to become a front runner on sustainability by continuous focus and innovations on reduction of emissions and waste production Vistin is one out of two European Metformin manufacturer, and the only one with a dedicated facility Vistin Pharma’s long-term vision is to have no negative impact on environment, people and local community by the Company’s presence. Vistin Pharma are proud of the sustainability achievements, the track record of deliverables and ongoing ESG focus and investments to further reduce the Company’s carbon footprint.”
Annual report 2024A · The company itself
Inventories
Macro
StrategyPositive impact: strengthens
“Vistin will be keeping a larger than normal level of raw material safety stock due to the current volatility in freight lead times.”
Annual report 2024A · The company itself
M&A and consolidation
Macro
StrategyPositive impact: strengthens
“In Q1 2024 Vistin acquired 15% of CF Parma in Budapest.”
Annual report 2024A · The company itself
Geopolitical uncertainty
Macro
DriverPositive impact: strengthens
“We also see the reshoring trend where global pharmaceutical producers look for local European supply of critical API’s due to the shifting geopolitical situation.”
Annual report 2024A · The company itself
DriverNegative impact: weakens
“The delivery time of raw materials from Asia has during 2024 been longer and more volatile than normal due to the Red Sea situation where ships need to sail via Africa to reach Europe.”
Annual report 2024A · The company itself
DriverPositive impact: strengthens
“The vulnerability for drug supplies during both the corona epidemic and the Ukraine situation has been an eye opener for the authorities, and the need for near shoring seems only to increase. Vistin is strategically well positioned to benefit from the expected stronger demand for local supplies from Europe going forward.”
Annual report 2024A · The company itself
Chains out: this strengthens Defence budgets, strengthens Energy security, strengthens Tariffs and trade policy, weakens Global trade volumes, strengthens Sea freight and freight rates, weakens Reconstruction of Ukraine
Inflation
Macro
DriverNegative impact: weakens
“Being a producer of Metformin in Norway and Europe of high volumes, the production cost of each unit is vital in being able to offer our customers and partners competitive prices and at the same time offer our investors and owners a reasonable return on investment.”
Annual report 2024A · The company itself
Chains out: this weakens Consumer spending, strengthens Interest rates
Asia and emerging markets
Geography
DriverPositive impact: strengthens
“There is also growth in the number of people in low- and middle-income countries who get diagnosed and put on Metformin - being an efficient, cheap and safe drug treatment.”
Annual report 2024A · The company itself
Consumer preference shifts
End markets
DriverPositive impact: strengthens
“Vistin Pharma’s customers are to a growing extent also requesting and expecting their suppliers to support the shift towards a sustainable future, and Vistin is strategically well positioned to fulfill these needs being situated in Norway with renewable hydropower and stable environmental focus.”
Annual report 2024A · The company itself
Chains out: this mixed effect Beer and beverages
GLP-1 and obesity treatment
Technology
DriverMixed impact: mixed
“We have seen this with the DDP4 combination products, the SGLT2 revolution past years and now also with the GLP-1 diabetes type 2 treatment with weight reducing effect. However, Metformin is used as baseline treatment and the combination drugs are typically added on top of Metformin, hence the future of Metformin looks positive.”
Annual report 2024A · The company itself
Chains in: US drug pricing policy weakens
Chains out: this mixed effect Healthcare and hospitals
Sea freight and freight rates
Raw materials and inputs
InputNegative impact: weakens
“The delivery time of raw materials from Asia has during 2024 been longer and more volatile than normal due to the Red Sea situation where ships need to sail via Africa to reach Europe.”
Annual report 2024A · The company itself
Chains in: Geopolitical uncertainty strengthens
Wind power
Technology
InputNegative impact: weakens
“Vistin Pharma’s customers are to a growing extent also requesting and expecting their suppliers to support the shift towards a sustainable future, and Vistin is strategically well positioned to fulfill these needs being situated in Norway with renewable hydropower and stable environmental focus.”
Annual report 2024A · The company itself
Chains in: Interest rates weakens, Energy security strengthens
Chains out: this strengthens Steel, strengthens Rare earths and critical raw materials, strengthens Renewables auctions and subsidies, strengthens Power grid expansion
Europe
Geography
Geography
“We also see the reshoring trend where global pharmaceutical producers look for local European supply of critical API’s due to the shifting geopolitical situation.”
Annual report 2024A · The company itself
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 0.43 bn NOK |
| Revenue growth vs. the year before, same method | -1.4 % |
| EBITDA reported by the company | N/A |
| Net debt debt incl. leasing minus cash | N/A |
| Diluted EPS per share | 1.42 NOK |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | ✓ |
| Growing | ✗ |
| Healthy balance sheet | N/A |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (NOK), not converted to DKK. Quotes are shown as the company's own words in the report's original language.